Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?

Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?

Despite a slower start this year, Gilead appears to be in pretty good shape to resume its momentum. CEO Dan O'Day stated in the press release announcing the numbers, "2022 marked Gilead's strongest full-year growth in our base business since HCV sales peaked in 2015." Is Gilead Sciences stock a buy after its strongest results in seven years?